Clinical Trials

Title   [817026-8] A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL).
Description   This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) patients.
IRB Number   16-063
Treatment   Oncology - Leukemia
Status   Active
Principal Name   David Clarkson, M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us